Dani Qin | Cardiovascular Disease | Best Researcher Award

Dr. Dani Qin | Cardiovascular Disease | Best Researcher Award

Yixing People's Hospital | China

Author Profiles

Scopus

Orcid

Early Academic Pursuits

Qin Dani began her academic journey with a strong foundation in pediatrics, completing her studies at a prestigious medical university and further pursuing advanced training. Her dedication to continuous learning is evident as she continues doctoral studies at a reputed university. Her academic background laid the groundwork for her clinical expertise and research orientation in pediatric healthcare.

Professional Endeavors

She has established herself as a key figure in the Department of Pediatrics at Yixing People's Hospital, where she has been contributing her expertise for many years. During her career, she also pursued advanced studies and training at well-regarded medical institutions, which broadened her clinical skills and enriched her professional development. She currently holds a leadership role as an Associate Chief Physician and plays an active part in pediatric development teams, shaping the direction of child healthcare services.

Contributions and Research Focus

Her clinical work spans the diagnosis and treatment of a wide spectrum of pediatric conditions, with particular strengths in infant and toddler health care, respiratory disorders, digestive system diseases, and neonatal health management. She has led several important research projects at provincial and municipal levels, demonstrating her commitment to bridging clinical practice with academic research. Her published works reflect a dedication to advancing pediatric medicine through evidence-based studies and practical insights.

Impact and Influence

Through her leadership and expertise, she has significantly contributed to improving pediatric care standards in her community and beyond. Her ability to manage both common and critical pediatric illnesses has earned her recognition among colleagues and institutions alike. Her influence extends to mentoring young professionals, thereby fostering the next generation of pediatric specialists.

Academic Cites

She has authored numerous academic publications in both international and national journals, with multiple contributions recognized in core and indexed platforms. Her scholarly work has been acknowledged through prestigious awards in natural science and academic excellence, showcasing her impact in both scientific and clinical communities.

Legacy and Future Contribution

Her career trajectory reflects a deep commitment to pediatric medicine, both in clinical practice and academic advancement. With her ongoing doctoral research, she is expected to make further strides in pediatric healthcare innovations. Her legacy will likely continue through her contributions to research, her role in nurturing young professionals, and her influence on public health standards in pediatrics.

Recognition and Honors

She has received several commendations from healthcare authorities and academic institutions for her outstanding contributions, including recognition for advanced individual achievements and excellence in academic publications. These accolades highlight her dedication, professionalism, and long-term impact in the medical field.

Conclusion

Qin Dani exemplifies the qualities of an accomplished physician, researcher, and academic leader. Her blend of clinical expertise, research achievements, and commitment to advancing pediatric medicine has left a lasting mark on both medical practice and scientific scholarship. With a proven record of excellence and continued pursuit of innovation, she stands as a role model in the field of pediatrics, poised to make even greater contributions in the years ahead.

Notable Publications

"Methionine sulfoxide suppresses adipogenic differentiation by regulating the mitogen‐activated protein kinase signaling pathway"

Authors: Dani Qin; Yong Lei; Wen Xie; Qiuju Zheng; Zhou Peng; Yiwen Liu; Biao Dai; Tieliang Ma; Ping
Journal: Cell Biology
Year: 2023

"Effects of miR-19b Overexpression on Proliferation, Differentiation, Apoptosis and Wnt/β-Catenin Signaling Pathway in P19 Cell Model of Cardiac Differentiation In Vitro"

Authors: Da-Ni Qin; Lingmei Qian; De-Liang Hu; Zhang-Bin Yu; Shu-Ping Han; Chun Zhu; Xuejie Wang;
Journal: Cell Biochemistry and Biophysics
Year: 2013

Mohammed Ahmed Akkaif | Cardiovascular Pharmacology | Best Researcher Award

Dr. Mohammed Ahmed Akkaif | Cardiovascular Pharmacology | Best Researcher Award

Dr. Mohammed Ahmed Akkaif, Fudan University, China

Dr. Mohammed Ahmed Akkaif is a Postdoctoral Researcher in the Department of Cardiology at Fudan University, China. He earned his Ph.D. in Clinical Pharmacy from Universiti Sains Malaysia in 2023, specializing in precision medicine, pharmacogenetics, and cardiology. A Young Ambassador for the European Association of Preventive Cardiology (2022–2024), he has published 34 peer-reviewed articles, with 29 indexed in SCI, and has over 2,179 citations. Recognized with the Young Researchers Award (ESC Asia 2022), he is a reviewer for 50+ high-impact journals. His research focuses on optimizing antithrombotic drug therapies through pharmacometabolomics for personalized cardiovascular treatment.

AUTHOR PROFILE

Scopus Profile

Orcid Profile

Google Scholar Profile

🎓EARLY ACADEMIC PURSUITS:

Dr. Mohammed Ahmed Akkaif began his academic journey with a strong foundation in Clinical Pharmacy at Universiti Sains Malaysia, where he completed his Doctor of Philosophy (PhD) in July 2023. During his PhD, he focused on the intersection of clinical pharmacy and biotechnology, gaining expertise in personalized and precision medicine. His academic accomplishments included publishing 10 articles (8 in SCI Q1 and Q2 journals) and presenting at six international conferences. This period also saw him design innovative approaches to enhance antithrombotic drug treatment, particularly through CYP2C19 genotype-guided antiplatelet therapy.

💼PROFESSIONAL ENDEAVORS:

Currently, Dr. Akkaif serves as a Postdoctoral Researcher in the Department of Cardiology at Fudan University’s Qingpu Branch of Zhongshan Hospital, China. His role involves leading advanced research in cardiovascular medicine, with a specialized focus on the clinical application of personalized medicine in cardiology. Additionally, he has served as a Young Ambassador for the European Association of Preventive Cardiology (EAPC) from 2022 to 2024, demonstrating his commitment to advancing heart health on a global scale. He has also contributed his expertise to several prestigious journals, with over 50 reviews in high-impact journals such as Journal of the American Heart Association and Arteriosclerosis, Thrombosis, and Vascular Biology.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOVASCULAR PHARMACOLOGY:

Dr. Akkaif’s research is primarily focused on pharmacogenetics and pharmacometabolomics, with a goal of improving personalized treatment strategies in cardiology. His work delves into the optimization of antithrombotic drug therapies through genetic and metabolic profiling, which holds the potential to revolutionize treatment protocols, making them more tailored to individual patient profiles. His research also bridges the gap between clinical pharmacy and biotechnology, aiming to develop more effective, individualized approaches to cardiovascular health.

🌍IMPACT AND INFLUENCE:

Dr. Akkaif’s contributions have already made a significant impact on both academic research and the practical application of precision medicine. He has been honored with the Young Researchers Award at the 2022 ESC Asia Conference in Singapore, highlighting his early recognition in the field. His research has also led to the publication of 34 peer-reviewed articles, with 29 of them indexed in SCI (Clarivate), reflecting his growing influence in the field of cardiovascular pharmacology. His work has contributed to advancing the understanding of genetic factors in drug response, and his findings are regularly cited by researchers and clinicians alike.

📚ACADEMIC CITATIONS AND RECOGNITION:

Dr. Akkaif’s publications have earned him considerable academic recognition, with a cumulative citation count of 2,179 as of now. This citation count reflects the profound influence his work has had on the scientific community, particularly in the areas of pharmacogenetics, pharmacometabolomics, and cardiology. His ability to produce impactful, high-quality research is evident through his consistent presence in top-tier journals, where his findings continue to shape the discourse on personalized medicine.

🌟LEGACY AND FUTURE CONTRIBUTIONS:

As Dr. Akkaif continues his postdoctoral work at Fudan University, his future contributions are poised to expand on his research in precision medicine and cardiology. Given his accomplishments thus far, his research promises to lead to more personalized treatment options for cardiovascular diseases, potentially transforming clinical practices and improving patient outcomes globally. His ongoing efforts in understanding the genetic and metabolic factors influencing drug efficacy will likely place him at the forefront of the personalized medicine movement, paving the way for future innovations in the medical field.

🏆KEY AWARDS AND HONORS:

  • Young Researchers Award at the 2022 ESC Asia Conference (Singapore)

  • Second Prize for the Young Investigator Award at the ESC Asia Congress in Singapore 2022

  • Young Ambassador of the European Association of Preventive Cardiology (EAPC) (2022–2024)

  • Reviewing Excellence for over 50 high-impact SCI Q1 and Q2 journals

🌍CONCLUSION:

Dr. Mohammed Ahmed Akkaif’s groundbreaking research in precision medicine and cardiology continues to shape the future of personalized healthcare. With a strong academic background, numerous publications, and recognition through prestigious awards, his work is making significant contributions to improving cardiovascular treatments. His role as a Young Ambassador for the European Association of Preventive Cardiology further highlights his dedication to global health. As he advances his postdoctoral research at Fudan University, Dr. Akkaif’s future endeavors hold the potential to revolutionize clinical practices, particularly in pharmacogenetics and pharmacometabolomics, ensuring more effective and individualized patient care.

TOP NOTABLE PUBLICATIONS:

Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in …

Authors: AJ Ferrari, DF Santomauro, A Aali, YH Abate, C Abbafati, H Abbastabar, …

Journal: The Lancet

Year: 2024

Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease …

Authors: M Brauer, GA Roth, AY Aravkin, P Zheng, KH Abate, YH Abate, C Abbafati, …

Journal: The Lancet

Year: 2024

Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the …

Authors: The Lancet

Year: 2024

Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050

Authors: M Naghavi, SE Vollset, KS Ikuta, LR Swetschinski, AP Gray, EE Wool, …

Journal: The Lancet

Year: 2024

Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021

Authors: SE Vollset, HS Ababneh, YH Abate, C Abbafati, R Abbasgholizadeh, …

Journal: The Lancet

Year: 2024

Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

Authors: VL Feigin, MD Abate, YH Abate, S Abd ElHafeez, F Abd-Allah, …

Journal: The Lancet Neurology

Year: 2024

Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021

Authors: NV Bhattacharjee, AE Schumacher, A Aali, YH Abate, R Abbasgholizadeh, …

Journal: The Lancet

Year: 2024

The Role of Genetic Polymorphism and Other Factors on Clopidogrel Resistance (CR) in an Asian Population with Coronary Heart Disease (CHD)

Authors: MA Akkaif, NAA Daud, A Sha’aban, ML Ng, MAS Abdul Kader, DA Noor

Journal: Molecules

Year: 2021

A review of the effects of ticagrelor on adenosine concentration and its clinical significance

Authors: MA Akkaif, ML Ng, MASA Kader, NAA Daud, A Sha’aban, B Ibrahim

Journal: Pharmacological Reports

Year: 2021

National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990–2021, and forecasts up to 2050

Authors: M Ng, X Dai, RM Cogen, M Abdelmasseh, A Abdollahi, A Abdullahi, …

Journal: The Lancet

Year: 2024